Sunday, February 15, 2026 2/15/2026

Antibody mediated immunity against Klebsiella pneumoniae

Award Number: R01AI175345
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2023
PERIOD OF PERFORMANCE END DATE: 10/31/2028

Group Awards By:

View Award Description

Antibody mediated immunity against Klebsiella pneumoniae - PROJECT SUMMARY Klebsiella pneumoniae has emerged as a critical human pathogen in the United States and globally. In the United States, K. pneumoniae is the third most common cause of hospital-acquired infections and accounts for 20% of deaths attributable to antibiotic-resistant bacteria. In low- and middle-income countries, K. pneumoniae is a leading cause of childhood mortality and neonatal sepsis. Despite the rising importance of this pathogen, there are no U.S. Food and Drug Administration or World Health Organization-approved vaccines for K. pneumoniae. Our project is designed to address three critical knowledge gaps related to the development of Klebsiella vaccines. First, although a quadrivalent O-antigen vaccine for K. pneumoniae has been proposed, there is insufficient evidence to show that the inclusion of only four O-types would provide sufficient protection against the nine structural subtypes of these K. pneumoniae O-antigens. To address this knowledge gap, we will determine whether human infection with each K. pneumoniae O-antigen subtype results in cross-specific antibody responses against other K. pneumoniae subtypes. This research will provide new and detailed information on the specificity of human O-antigen responses to K. pneumoniae and inform the antigenic composition of a K. pneumoniae O-antigen vaccine. Second, our proposed experiments will determine which K. pneumoniae antigens contribute to functional human antibody responses the bacterium. Specifically, we will determine whether antibody responses to both the capsular (K-) and O-antigens the bacteria through interactions with phagocytic cells and complement. This is important because such functional responses are likely to mediate protection against K. pneumoniae infection. Third, we will determine which types of antibodies are associated with protection against intestinal colonization with K. pneumoniae. If we identify antibodies that are correlated with protection against K. pneumoniae, this will represent a groundbreaking finding and aid in the development of vaccines for this important pathogen. In summary, we expect the proposed studies to generate fundamental insights into immunity against this pathogen and aid in the development and assessment of K. pneumoniae vaccines. Our proposed work will provide critical data to inform the antigenic composition of K. pneumoniae vaccines and new proxy measures to assess vaccine efficacy in pre-clinical and early phase vaccine trials. These insights are urgently needed to address the growing global threat of antibiotic-resistant K. pneumoniae.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $719,385 )
2026	2026	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	3	12/30/2025	NON-COMPETING CONTINUATION	$600,956
2026	2026	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	003	3	2/6/2026	NON-COMPETING CONTINUATION	$0
2026	2026	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	3	1/13/2026	SUPPLEMENT FOR EXPANSION	$19,000
2026	2026	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	002	3	1/14/2026	SUPPLEMENT FOR EXPANSION	$99,429
														Subtotal = $719,385

Issue Date FY: 2025 ( Subtotal = $693,822 )
2025	2025	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	2	10/31/2024	NON-COMPETING CONTINUATION	$693,822
														Subtotal = $693,822

Issue Date FY: 2024 ( Subtotal = $730,301 )
2024	2024	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	1	5/24/2024	NEW	$69,680
2024	2024	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	11/30/2023	NEW	$660,621
														Subtotal = $730,301

Grand Total All Awards = $2,143,508

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Antibody mediated immunity against Klebsiella pneumoniae

Award Number: R01AI175345

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2023

PERIOD OF PERFORMANCE END DATE: 10/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer